Trial Status: Recruiting Clinical Trials Identifier: NCT06797869 Trial Name: A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy Diabetes Type: Type 2 diabetes Trial Sponsor: Novo Nordisk A/S Why is this study important
Within experimental and pharmacological research, GLP-1 pathways are widely investigated for their influence on glucose metabolism, energy balance, and appetite control mechanisms
However, the NHANES-eligible population differs from the trial cohort in key clinical characteristics, including a higher prevalence of chronic kidney disease and a lower prevalence of coronary artery disease
Shengjun Ji, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Step 4 Prescription Compounded and Shipped Within 1 Business Day Once payment is received and the prescription is issued, it is sent to a licensed U.S
Semaglutide effectiveness is driven by hormonal responsiveness , not by dose size alone